BMRA
BIOMERICA INC
NASDAQ · Healthcare · Medical - Devices · US
$1.76
−4.86%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.3M | 4.5M | 5.3M | 5.4M | 5.3M |
| Cost of Revenue | 4.3M | 4.1M | 4.8M | 4.8M | 4.9M |
| Gross Profit | 39.0K | 362.0K | 498.0K | 611.0K | 446.0K |
| Operating Expenses | |||||
| R&D Expense | 782.0K | 788.0K | 1.0M | 1.5M | 1.6M |
| SG&A Expense | 4.7M | 4.9M | 4.6M | 5.5M | 6.1M |
| General & Admin Expense | 1.1M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 1.0K |
| Total Operating Expenses | 5.5M | 5.7M | 5.6M | 7.0M | 7.7M |
| Cost and Expenses | 9.8M | 9.8M | 10.4M | 11.8M | 12.6M |
| Operating Income (EBIT) | (5.4M) | (5.3M) | (5.1M) | (6.4M) | (7.2M) |
| Non-Operating | |||||
| Interest Income | 110.0K | 1.2M | 165.0K | 431.0K | 133.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 110.0K | 1.2M | 165.0K | 431.0K | 133.0K |
| Other Non-Op Income/Expense | 447.0K | 1.6M | 165.0K | 431.0K | 134.0K |
| Non-Operating Income (excl Interest) | (53.0K) | — | (165.0K) | (431.0K) | (134.0K) |
| EBT (Pre-Tax Income) | (5.0M) | (3.8M) | (5.0M) | (5.9M) | (7.1M) |
| Income Tax Expense | 25.0K | 23.0K | 1.0K | 42.0K | 51.0K |
| Bottom Line | |||||
| Net Income | (5.0M) | (3.8M) | (5.0M) | (6.0M) | (7.1M) |
| Earnings from Cont. Ops | (5.0M) | (3.8M) | (5.0M) | (6.0M) | (7.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.0M) | (3.8M) | (5.0M) | (6.0M) | (7.1M) |
| Per Share | |||||
| Basic EPS | ($1.63) | ($1.30) | ($2.16) | ($0.36) | ($0.50) |
| Diluted EPS | ($1.63) | ($1.30) | ($2.16) | ($0.36) | ($0.50) |
| Revenue Per Share | $1.32 | $1.53 | $2.31 | $0.32 | $0.38 |
| Shares | |||||
| Basic Shares Outstanding | 3.3M | 2.9M | 2.3M | 16.8M | 14.2M |
| Diluted Shares Outstanding | 3.3M | 2.9M | 2.3M | 16.8M | 14.2M |
| Profitability Metrics | |||||
| EBITDA | (5.0M) | (4.9M) | (4.6M) | (5.6M) | (6.7M) |
| D&A | 334.0K | 421.0K | 400.0K | 374.0K | 351.0K |
| EBIT | (5.4M) | (5.3M) | (5.0M) | (5.9M) | (7.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026